HK Stock Market Move | LEADS BIOLABS-B(09887) surges nearly 6%, TCE dual monoclonal antibody LBL-034 receives FDA fast track qualification.

LEADS BIOLABS-B(09887) rose by nearly 6%, reaching 4.63% at the time of reporting, at 62.2 Hong Kong dollars, with a trading volume of 114.228 million Hong Kong dollars. On the news front, Viela Bio announced that the company's GPRC5D/CD3 bispecific antibody LBL-034, developed independently by the company based on its proprietary TCE technology platform LeadsBody, has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM). Following the FDA orphan drug designation in October 2024, this marks another important milestone in the product's international development path, signaling further recognition of its clinical value and development strategy by international regulatory agencies. LBL-034 is a humanized bispecific T cell engager targeting GPRC5D and CD3.